UK markets open in 3 hours 27 minutes
  • NIKKEI 225

    29,109.52
    +160.79 (+0.56%)
     
  • HANG SENG

    28,842.13
    +103.23 (+0.36%)
     
  • CRUDE OIL

    71.26
    +0.35 (+0.49%)
     
  • GOLD FUTURES

    1,866.10
    -13.50 (-0.72%)
     
  • DOW

    34,479.60
    +13.40 (+0.04%)
     
  • BTC-GBP

    27,580.97
    +2,642.13 (+10.59%)
     
  • CMC Crypto 200

    972.74
    +30.92 (+3.28%)
     
  • ^IXIC

    14,069.42
    +49.12 (+0.35%)
     
  • ^FTAS

    4,068.33
    +24.32 (+0.60%)
     

US Rosacea Market Size & Forecasts to 2025: Major Players are Vyne Therapeutics, Galderma, Sol-Gel Technologies, and Abbvie

·3-min read

Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "The US Rosacea Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering.

The US Rosacea Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition), provides a detailed analysis of the US rosacea market with market sizing and growth pattern.

The analysis includes rosacea market in terms of value, volume and number of patients seeking treatment. The report also provides an overview of the US dermatology drugs market in terms of value and market share by segments.

The US rosacea market has grown over the past few years and is projected to grow at a high growth rate on the back of rising incidence of disease, and aging population.

The growth in the market will be driven by unhealthy eating habits and environmental factors, rising disposable income, ageing population, escalating healthcare expenditure, high prevalence of rosacea, etc. Yet the market growth is restrained by factors such as lack of awareness and knowledge and stringent government regulations for the approval of new drugs.

The COVID-19 pandemic has led to decline in appointments of rosacea patients with dermatologists mainly due to travel restrictions. Thereby, impacting the market growth negatively as far as 2020 is concerned.

Furthermore, the report also assesses the key opportunities available in the market and summarizes the dynamic forces that are and will be accountable for growth of the industry. Growth of the US rosacea market has also been forecasted for the period 2020-2024, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.

Vyne Therapeutics (Foamix Pharmaceuticals Ltd.), Galderma, Sol-Gel Technologies Ltd., and Abbvie (Allergan Plc) are some of the major players whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies adopted by respective companies.

Key Topics Covered:

1. Executive Summary

2. Introduction
2.1 Overview of Rosacea
2.1.1 Symptoms of Rosacea
2.1.2 Causes of Rosacea
2.1.3 Types of Rosacea
2.1.4 Treatment of Rosacea

3. The US Market Analysis
3.1 The US Dermatology Drugs Market Analysis
3.1.1 The US Dermatology Drugs Market by Value
3.1.2 The US Dermatology Drugs Market by Segments (Rosacea and Others)
3.2 The US Rosacea Market Analysis
3.2.1 The US Rosacea Market by Value
3.2.2 The US Rosacea Market by Volume
3.2.3 The US Rosacea Market by Number of Patients Seeking Treatment

4. Impact of COVID-19
4.1 Impact on the US Rosacea Market
4.1.1 Potential Opportunities

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Aging Population
5.1.2 Rising Disposable Personal Income
5.1.3 Escalating Healthcare Expenditure
5.1.4 Unhealthy Eating Habits and Environmental Factors
5.1.5 High Prevalence Rate of Rosacea
5.2 Challenges
5.2.1 Lack of Awareness
5.2.2 Stringent Government Regulations
5.3 Market Trends
5.3.1 Approval of New Drugs

6. Competitive Landscape
6.1 The US Rosacea Market Players: A Financial Comparison
6.2 The US Rosacea Drugs Competitive Landscape
6.3 The US Rosacea Market Players Competitive Landscape

7. Company Profiles
7.1 Business Overview
7.2 Financial Overview
7.3 Business Strategy

  • Vyne Therapeutics (Foamix Pharmaceuticals Ltd.)

  • Galderma

  • Sol-Gel Technologies Ltd.

  • Abbvie (Allergan Plc)

For more information about this report visit https://www.researchandmarkets.com/r/7enubq

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900